According to the American Cancer Society, prostate cancer claims approximately 27,000 of us each year, the vast majority of our deaths are a result of recurrent metastatic disease. Metastatic prostate cancer occurs when tumor cells spread to other locations in the body and start to grow. Currently, when you start Chemotherapy the only way to [...]
On the close horizon is a new drug that will treat the many side effects of a hormone blockade (ADT). On Monday, positive results of a phase III clinical trial of toremifene citrate was released to the press. GTX Inc. (GTXI), the biopharmaceutical company that has been conducting the trial says that by this coming [...]
There is exciting news out of the 2008 Genitourinary Cancers Symposium in San Francisco. An abstract (American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium (GCS): Abstract 85) presented at the conference described a retrospective study that strongly suggests that salvage radiotherapy reduced the risk of dying from prostate cancer by more than 60% for [...]
I received an e-mail this morning from Leslie who was the producer and director of the short video I filmed about the Provenge issue at the FDA. (you can view the video at: Joel's Provenge Video Leslie asked that I sign a petition asking for a formal inquiry into the conflict of interest (COI) issues [...]
The FDA has approved the first generic versions of Fosamax (alendronate sodium tablets), used to treat osteoporosis. Osteoporos is a condition that causes thinning and weakening of bones and is often one of the many significant side effects from Hormone Therapy. Teva Pharmaceuticals USA has received approval to manufacture alendronate sodium tablets in three once-daily [...]